Revelation Biosciences

Revelation Biosciences is a clinical life sciences company dedicated to developing immunology-based therapies for the prevention and treatment of diseases. The company is developing several candidate products. REVTx-99, the primary therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS-CoV-2 infection. Expansion plans for the REVTx-99 treatment indications target the early treatment and prevention of respiratory viral infections such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx-200 is an intranasal immunomodulator that can be used in conjunction with intramuscular vaccines to achieve more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.